Steven Nijs

机构：Janssen (Belgium), Argenx (Belgium)

发表论文 36 篇 · 总被引 1354 次 · h-index 17

代表论文

• Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) (2018 · The Lancet · 被引 345)
• Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study (2020 · The Lancet HIV · 被引 92)
• Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase on Phenotypic Susceptibility and Virologic Response to Etravirine (2011 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 被引 78)
• First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector (2018 · The Journal of Infectious Diseases · 被引 45)
• Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial (2024 · The Lancet Infectious Diseases · 被引 41)
• Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study (2022 · The Journal of Infectious Diseases · 被引 37)